Volume 2 Supplement 1

Abstracts of the 2nd European Symposium on Focused Ultrasound Therapy

Open Access

Hyperthermic ablation by UltraSound Guided High Intensity Focused Ultrasound (USgHIFU) plus Systemic Chemotherapy (SC) for locally advanced pancreatic cancer: the secret of longer survival

  • Joan Vidal-Jove1,
  • Eloi Perich1,
  • Marta Garcia-Bernal1 and
  • Manuel Alvarez del Castillo1
Journal of Therapeutic Ultrasound20142(Suppl 1):A6

https://doi.org/10.1186/2050-5736-2-S1-A6

Published: 10 December 2014

We describe results in unresectable pancreatic tumors treated with USgHIFU hyperthermia ablation plus adjuvant chemotherapy.

Materials and methods

Forty three cases of non resectable pancreatic tumors were treated from March 2010 to March 2013, and all of them underwent systemic chemotherapy. Clinical responses (thermical ablation achieved) were measured by image techniques. They were 29 Stage III cases and 14 Stage IV cases. Complications were also analyzed.

Results

Clinical responses (ablation obtained) were 82% in all cases, sustained at 8 weeks of the procedure. We obtained 10 complete responses (25%) at the end of the combined treatment, 9 from stage III patients and 2 from stage IV. Major complications included severe pancreatitis with GI bleeding (1), skin burning grade III that required plastic surgery (2). No deaths were registered. Median Survival was 13 month (6 mo - 2.7 year).

Conclusion

HIFU plus SC is a potentially effective and safe modality for the treatment of unresectable pancreatic cancer.

Authors’ Affiliations

(1)
Hospital University Mutua Terrassa

Copyright

© Vidal-Jove et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement